Corneal Defect Clinical Trial
Official title:
To Evaluate the Local Pharmacokinetic Characteristics of Single Administration of Germinal Peptide Eye Drops in Healthy Volunteers in a Phase I Clinical Study
The subjects of this study were healthy subjects, who were given medicine in a single dose group: 0.004%.
Tear collection was conducted on the single dose D1 (that is, the day of administration). Collection points: 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 12 h after administration.Each time 5-50 mg (generally 20 mg), a total of 160-1600 mg of tears will be collected (during the screening period, all subjects will retain the tear samples collected by the Schirmer filter paper, among which, qualified tear samples will be used for blank samples or methodological investigation.After administration, only 1 tear collection site will be collected for each subject. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03662971 -
Evaluate the Tolerance, Safety and Pharmacokinetics of Germinal Peptide Eye Drops in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT04521140 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Corneal Transplant Surgery
|
Phase 4 | |
| Completed |
NCT04975971 -
A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery
|
||
| Recruiting |
NCT04626583 -
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
|
Phase 1 | |
| Recruiting |
NCT05626478 -
Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery
|
Phase 4 | |
| Recruiting |
NCT05204329 -
Safety of Topical Mesenchymal Stromal Cell Secretome for Ocular Surface Disease
|
Early Phase 1 | |
| Recruiting |
NCT04228926 -
Evaluating the Efficacy and Safety of ZKY001 Eye Drops in the Treatment of Corneal Epithelial Defects
|
Phase 2 | |
| Not yet recruiting |
NCT05458661 -
Feasibility Investigation of Biometry and Tomography Measurements in a Heterogeneous Patient Cohort
|
N/A |